GAITHERSBURG, Md., Oct. 29,
2024 /PRNewswire/ -- LakeShore Biopharma Co.,
Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a
global biopharmaceutical company dedicated to discovering,
developing, manufacturing, and delivering new generations of
vaccines and therapeutic biologics for infectious diseases and
cancer, today announced that it has received a written notice (the
"Compliance Notice") from the Listing Qualifications Department of
The Nasdaq Stock Market LLC ("Nasdaq") dated October 21, 2024, informing the Company that it
has regained compliance with the minimum bid price requirement set
forth under the Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid
Price Requirement").
As previously announced, the Company was notified by Nasdaq on
October 24, 2023 that the Company was
not in compliance with the Minimum Bid Price Requirement as the
closing bid price of the Company's ordinary shares was below
$1.00 per share for a period of 30
consecutive business days.
According to the Compliance Notice, the Company regained
compliance with the Minimum Bid Price Requirement because the
closing bid price of the Company's ordinary shares have been
$1.00 per share or greater for 11
consecutive business days, from October 4,
2024, to October 18, 2024, and
the matter is now closed.
About LakeShore Biopharma
LakeShore Biopharma, previously known as YS Biopharma, is a
global biopharmaceutical company dedicated to discovering,
developing, manufacturing, and delivering new generations of
vaccines and therapeutic biologics for infectious diseases and
cancer. It has developed a proprietary PIKA® immunomodulating
technology platform and a new generation of preventive and
therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B,
Influenza, Shingles, and other virus infections. The Company
operates in China, the United States, Singapore, and the
Philippines, and is led by a management team that combines
rich local expertise and global experience in the biopharmaceutical
industry. For more information, please visit
investor.lakeshorebio.com.
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: LakeShoreBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lakeshore-biopharma-regains-compliance-with-nasdaq-minimum-bid-price-requirement-302289990.html
SOURCE LakeShore Biopharma Co., Ltd